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Interventional Management of
Esophagorespiratory Fistula
An esophagorespiratory fistula (ERF) is an often fatal consequence of
esophageal or bronchogenic carcinomas. The preferred treatment is placement
of esophageal and/or airway stents. Stent placement must be performed as
quickly as possible since patients with ERFs are at a high risk for aspiration pneu-
monia. In this review, choice of stents and stenting area, fistula reopening and its
management, and the long-term outcome in the interventional management of
malignant ERFs are considered. Lastly, a review of esophagopulmonary fistulas
will also be provided.
n esophagorespiratory fistula (ERF) is an abnormal communication
between the esophagus and the respiratory system; it is a devastating and
life-threatening complication of esophageal and bronchogenic carcino-
mas, according to most etiologies (1). An ERF develops in approximately 1-22% of
patients with an esophageal malignancy and in less than 1% of those with
bronchogenic carcinoma (1-3). An ERF develops either because of direct tumor
invasion and subsequent perforation or after radiation, laser therapy, chemotherapy or
pre-existing stents (primarily, esophageal stents), or a combination of these (1, 4) (Fig.
1). 
The diagnosis of ERFs is usually not simple because of the dysphagia caused by the
stenosis, which in turn occurs because of the cancer and the recurring aspiration result-
ing from the swallowing malfunction caused by paresis (3). Autopsy data indicate a
higher incidence of fistulas, thus suggesting that fistulas are more common in patients
than is usually diagnosed (3). ERFs can be confirmed based on clinical and endoscopic
findings. A history of repeated coughing associated with eating, drinking, or both, with
an increase in dysphagia and dyspnea are highly suggestive of an ERF. Endoscopic
findings are sometimes inadequate in demonstrating a fistula, in which case an esopha-
gogram is required. Esophagograms should be performed cautiously as aspiration
could occur during swallowing of the contrast medium. CT is very important for
assessing the extent of disease and pneumonia, as well as the relationship between the
fistula and the surrounding tissue for planning the stent placement. For airway
stenting, reconstructed CT images are very useful for measuring the distance between
the fistula and a carina or vocal cord, in the determination optimal stent length. 
Treatment should be begun immediately after the diagnosis is confirmed since the
usual cause of death in these patients is pulmonary sepsis resulting from chronic
aspiration through the fistula. Unfortunately, at the time of diagnosis, the patient’s
performance and disease status usually precludes aggressive surgical therapy, thus
leaving few therapeutic options (4). Esophageal intubation using conventional
unexpandable plastic prostheses was the treatment of choice for ERFs until the early
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A1990s; however, complications such as perforation,
hemorrhage, pressure necrosis, tube obstruction, tube
dislodgment, and tube migration were reported in approxi-
mately 15-40% of patients (5). To overcome these limita-
tions, several types of covered expandable metallic stents
have been used in the treatment of ERFs (1, 3-12). 
Traditionally, ERF means esophagotracheal or esophago-
bronchial fistulas. In the widest sense, an esophagopul-
monary fistula can also be included. In this review,
esophagotracheobronchial and esophagopulmonary fistulas
will be considered, giving special emphasis to their
interventional management. 
ESOPHAGOTRACHEOBRONCHIAL FISTULA
Interventional Management and Follow-Up
Surgical management is very limited. Seto et al. (13)
reported successful results in four patients that underwent
an esophageal bypass using a gastric bypass and cardios-
tomy. However, they also cited the need for further
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Fig. 1. Esophagobronchial fistula due to
pressure necrosis by esophageal stent.
Esophagogram (A) and bronchoscopy
(B) after esophageal stent removal
shows definite fistula (arrows) at
proximal end of stent site.
Esophagogram (C) and bronchoscopy
(D) after bronchial stent placement
(arrows), shows successful closure of
fistula. 
AB
CDclinical experience with more patients. This treatment is
palliative and involves the restoration of the ability to
ingest food and to prevent aspiration by inserting an
esophageal or airway stent in most cases. Radiation
therapy and chemotherapy are generally contraindicated
due to the concern regarding fistula enlargement caused by
tumor necrosis. A feeding gastrostomy or jejunostomy is
only occasionally used for palliation since these procedures
do not restore normal swallowing (11). 
Covered expandable metallic stents were introduced in
the mid-1990s and have shown a 67-100% stent closure
rate (1, 3-12). We previously reported the long-term
outcomes in 61 patients with malignant ERFs, each of
whom had undergone the insertion of a covered expand-
able metallic stents. Stent placement was technically
successful in all patients, and there were no immediate
procedural complications (1). The stent completely sealed
off the fistula in 80% (49 of 61) of the patients, and there
were no further aspiration symptoms (initial clinical
success) (Figs. 1, 2). Incomplete closure of the fistula
caused by spillage of material through a gap between the
proximal stent margin and the esophageal wall within
seven days after stent placement (initial clinical failure),
was seen in 12 (20%) of the 61 patients (1), and was due
to the ‘funnel phenomenon’ which is difficult to manage
despite the insertion of additional stents or glue injection to
seal the gap (14-16). For esophageal stenosis with ERFs,
18-mm-diameter stents were used. Whereas, for
esophageal stenosis without ERFs, 16-mm-diameter stents
were generally used. In the study by Balazs et al. (12),
which included 188 patients that underwent covered stent
placement for malignant ERFs, improvement of swallowing
and fistula closure were achieved in 77% of the patients
(144 of 188). 
A close follow-up of patients with ERFs is important
since non-sealing of a fistula after stent placement, and
reopening of a fistula after initial sealing, might cause
aspiration pneumonia which would certainly lead to the
rapid demise of the patient. To prevent further aspiration
pneumonia, an esophagogram obtained immediately after
stent insertion is crucial in order to confirm the sealing of
the fistula and subsequently allow a patient to eat a soft
diet. If there is persistent leakage through the fistula,
resulting from an incomplete stent expansion, a follow-up
esophagogram should be obtained 2-3 days after stent
placement in order to confirm stent expansion before food
intake is resumed (1). The protocol of a repeat esopha-
gogram at one week and then every one to two months
after the procedure is suggested to evaluate fistula closure
and stent patency or migration. This would also provide
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Fig. 2. Esophageal cancer with development of esophagobronchial fistula. Ingested contrast medium is aspirated into left bronchi (A).
Right anterior oblique (B) and anteroposterior (C) esophagograms obtained two days after placement of covered expandable metallic
stent (18 mm in diameter), shows complete closure of fistula. 
ABCearly detection of fistula reopening as well as long-term
outcomes. 
Selection of Stents and Stenting Area
Several kinds of covered esophageal stents are available
in the United States (i.e., Ultraflex stent, Wallstent, and Z
stent). In Korea, covered retrievable esophageal or airway
stents made by S & G Biotech and Taewoong Medical are
available; however, there are no randomized or controlled
trials to compare the outcomes of any of these stents when
used to treat malignant ERFs.
An understanding of the esophageal and airway anatomy
of patients with ERFs is critical to determine stent
placement into the esophagus, airway, or both. Airway
stenting, with or without esophageal stenting, is useful in
patients with Ivor Lewis esophagectomy, i.e., partial
esophagectomy with bowel interposition, substantial
airway stricture, previously placed esophageal stent, and
an ERF secondary to pressure necrosis of the esophageal
stent (1, 10, 11, 17) (Fig. 1).
The selection guide for determining the stenting area
could be summarized as follows (Fig. 3): 1) esophageal
stent placement if a patient has a stricture in the esopha-
gus, but with no or only mild airway stricture since an
esophageal stent can successfully treat both esophageal
stricture and a fistula; 2) airway stent placement if a
patient has no or only mild stricture in the esophagus, or
has moderate to severe stricture in the airway, since an
esophageal stent migrates well when esophageal stricture is
absent or mild, and an airway stent can treat an airway
stricture; or 3) both the airway and esophageal stent
placement when a patient has moderate to severe stricture
involving both the esophagus and the airway, since both
the airway and esophageal stents are necessary to treat a
stricture involving both the esophagus and the airway.
In the selected patients, as the insertion of a single stent
may be insufficient for palliation, placement of parallel
stents may be indicated for patients with symptoms caused
by malignant ERFs (11, 17) (Fig. 4). It is very important to
carefully evaluate the airway stenosis with CT scans or
bronchoscopes prior to esophageal stent placement, since it
is possible to develop tracheal compression caused by
expanding esophageal stents (17). Therefore, for insertion
of both esophageal and airway stents during the same
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AB
Fig. 3. Determination of stenting area in various types of esophagorespiratory fistula. 
A. Esophageal stenting is indicated when esophageal stricture is severe, but with no or only mild airway stricture. 
B. Airway stenting is indicated when esophageal and airway strictures are non-existent or mild. 
C. Airway stenting is indicated when airway stricture is severe, but without or with only mild esophageal stricture. 
D. Both airway and esophageal stenting is indicated when both esophageal and airway stenosis is severe. M and S denotes mild or
severe degree of stenosis, respectively. 
CDprocedure, airway insertion should precede the esophageal
stent insertion, since dyspnea could be aggravated immedi-
ately following the esophageal insertion.
Mechanical friction between the esophageal and airway
stents may cause pressure necrosis of the interposed tissue
between the two stents, thereby possibly resulting in a fatal
hemorrhage (10, 17, 18). Thus, parallel stenting should
only be performed after thoroughly reviewing a patient’s
clinical indications. 
Fistula Reopening and Management 
Reopening of a closed ERF is another life-threatening
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Fig. 5. Reopening of esophagobronchial fistula caused by food impaction. 
A. Initial lateral view shows fistula caused by esophageal cancer. Subsequently, placement of covered expandable stent was performed. 
B. Esophagogram obtained one month after stent placement, shows reopening of fistula (arrow) due to food impaction, which is seen as
filling defects within stent. 
C. This patient underwent passage of inflated balloon catheter (arrow) up and down occluded stent to displace impacted food into
stomach. 
D. Esophagogram obtained after cleansing stent, shows stent patency and disappearance of fistula.  
ABCD
Fig. 4. Esophageal cancer and esophagotracheal fistula. 
A. Lateral esophagogram shows esophagotracheal fistula (arrow) and segmental luminal narrowing in cervical esophagus. 
B. Radiograph obtained one week following esophageal stent placement shows diffuse tracheal narrowing (arrows). 
C. Radiograph obtained following tracheal stent placement to relieve dyspnea. 
D. Esophagogram obtained one week after tracheal stent placement shows good flow of contrast medium through esophageal stent
without visualization of fistula and fully expanded tracheal stent.
ABCDproblem because reopening of the fistula indicates a return
to the aspiration symptoms. In our large series report (1),
the fistula reopened in 17 (35%) of 49 patients with initial
clinical success at a mean follow-up time of 4.8 weeks. The
reopening was caused primarily by complications associ-
ated with the placed stent, i.e., stent occlusion caused by
tumor overgrowth or ingrowth, food impaction or granula-
tion tissue formation, stent migration, and stent covering
disruption (1, 6, 8, 14) (Fig. 5). Attention to dentition and
adequate chewing could limit food-impaction-related
problems. Furthermore, stent upgrade will be necessary in
order to minimize tumor ingrowth or overgrowth as well
as granulation tissue formation. 
In a report by Shin et al. (1), eight of 17 patients
underwent interventional treatment for reopened fistulas.
Balloon irrigation was performed to displace the impacted
food bolus into the stomach (Fig. 5). Balloon dilation and
stent placement were performed for reopening caused by
new granulation tissue formation; whereas, second stent
placement was performed for incomplete covering of the
fistula or stricture, or stent migration. Reopened fistulas
can be treated successfully using interventional manage-
ment if a patient’s general condition is not poor. 
Quality of Life and Long-Term Outcome
In a comparative study, health-related quality of life was
remarkably improved in the stenting group, compared
with the control group and the gastrostomy group in 35
patients with malignant ERFs (19). 
In two, large series reports (1, 12), mean patient survival
was reported to be 3.1-3.4 months. In one of these reports
(12), the survival benefit was significant in patients in the
stenting group (3.4 months) compared with the enteros-
tomy group (1.1 months), and the supportive management
group (1.3 months). In patients with stenting for malignant
ERFs, survival depends on the successful sealing of the
fistula (15.1 versus 6.2 weeks, p < 0.05) (1); therefore,
suggesting that control of pulmonary contamination can
provide the opportunity for both improved survival and
quality of life. 
ESOPHAGOPULMONARY FISTULA
Although the term ‘esophagorespiratory fistula’ is used
to describe all fistulas located between the esophagus and
airway tree, the fistula site is esophagotracheal in 52-57%
of patients and esophagobronchial in 37-40% (2, 20, 21).
In the remaining patients (3-11%), communication is
established peripherally through the lung parenchyma,
thus forming an esophagopulmonary fistula (2, 20, 21).
However, previous reports regarding stent placement in
patients with esophagopulmonary fistulas are very few
(22).
In our recent study (22), we determined that 14
Shin et al.
138 Korean J Radiol 11(2), Mar/Apr 2010
Fig. 6. Esophagopulmonary fistula caused by lung cancer. Esophagogram (A) and CT scan (B) show large lung abscess (arrows)
connected to esophagus. Immediate (C) and one-month (D) follow-up esophagograms show successful closure of fistula. 
AB C Desophagopulmonary fistulas were caused by esophageal (n
= 9) or bronchogenic (n = 5) carcinomas. Chemotherapy
and radiation therapy appeared to be highly associated
with fistula development, which occurred in 12 of our 14
study patients. At the time of stent placement, all patients
had aspiration pneumonia and 11 had lung abscesses
(79%), thus indicating lung contamination in all cases.
Stent placement was technically successful in all cases, and
clinical success, i.e., complete fistula sealing resulting in
resolution of the aspiration symptoms, occurred in 12
patients (86%) (Fig. 6). During follow-up, the fistula
reopened in two patients, who were subsequently treated
with clinical success.
In our recent report, the mean patient survival time was
101 days (22), and the cause of death was usually aspira-
tion pneumonia (13 of 14 patients). The survival period
seems to be similar to that of esophagotracheobronchial
fistulas, which range between 3.1-3.4 months (1, 12). Lung
abscesses decreased in size, but persisted even after stent
placement, probably because the natural drainage of lung
abscesses into the esophagus would be closed after stent
placement (22). Concomitant abscess drainage procedures
should thus be considered. 
To increase the length of patient survival, the diagnosis
of esophagopulmonary fistulas must be established early,
ideally before the onset of pneumonia or the development
of lung abscesses. High-risk patients with esophageal or
bronchogenic carcinomas and who undergo chemotherapy
or radiation therapy should be closely followed in order to
detect symptoms associated with fistula formation.
SUMMARY
Placement of covered expandable metallic stents is a safe
and effective palliative treatment for patients with ERFs.
Furthermore, although the initial clinical success rate was
poor and the rate of reopening was high, interventional
management may be effective for sealing off reopened
ERFs.
Placement of covered expandable metallic esophageal
stents can be a successful alternative for palliative
treatment of malignant esophagopulmonary fistulas.
However, persistence of lung abscesses and the worsening
of a patient’s clinical condition are frequently observed
even following stent placement.
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